Overview

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

Status:
RECRUITING
Trial end date:
2029-08-20
Target enrollment:
Participant gender:
Summary
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Phase:
PHASE3
Details
Lead Sponsor:
GlaxoSmithKline